Drug Trial Radar · NCT06072768
Dynamic Treatment Regiments for Glucocorticoid Tapering
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 9, 2023
Primary completion
Mar 1, 2029
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- University of Michigan
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't. This trial will look at different patient characteristics, including levels of inflammation in the body, differences in the way the brain processes sensory information, and certain hormone levels, to help researchers better understand why different people have these different responses to steroid tapering. The hypotheses include: * Greater or equal to ( ) 30% of participants in each arm will develop taper intolerance (either subjective, objective, or both) during the study period * Greater or equal to 60% of participants will reduce Glucocorticoid dose by at least 5 Milligrams per day during the study period
Conditions
- Rheumatoid Arthritis
Interventions
15-day taper prednisoneDrug
The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
150-day taper prednisoneDrug
The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with subjective taper intoleranceTime frame: Day 30 (15-day taper) or day 180 (150-day taper group)
- Number of participants with objective taper intoleranceTime frame: Day 30 (15-day taper) or day 180 (150-day taper group)
- Net glucocorticoid dose reductionTime frame: Day 30 (15-day taper) or day 180 (150-day taper group)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.